Since the standard treatment protocol for COVID-19 patients in critical condition has been accompanied by immunomodulators such as dexamethasone or tocilizumab (an IL-6 inhibitor), the usefulness of inflammatory biomarkers in predicting secondary bacterial infections has been unclear and has required further research. This evidence concerns the gene IL6 and COVID-19.